TNFSF10 and neoplasm: Our lab has previously designed and tested a liposomal formulation designed to target circulating tumor cells (CTCs) via conjugation of E-selectin, an adhesion molecule expressed by activated endothelium and involved in metastasis and inflammation, and TRAIL [32].